請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38835
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林峰輝(Feng-Huei Lin) | |
dc.contributor.author | Hsi-Chin Wu | en |
dc.contributor.author | 吳錫芩 | zh_TW |
dc.date.accessioned | 2021-06-13T16:48:25Z | - |
dc.date.available | 2005-07-20 | |
dc.date.copyright | 2005-07-20 | |
dc.date.issued | 2005 | |
dc.date.submitted | 2005-06-27 | |
dc.identifier.citation | http://paris.phys.virginia.edu/~pocanic/phys_304/tables/blood_vessel_anatomy.jpg
http://www.tmc.edu/thi/cad.html http://medinfo.ufl.edu/cme/grounds/cv/berceli/slide06.html http://www.mcghealth.org/Greystone/t_and_p/heart/TP142.html http://www.tmc.edu/thi/cabgrft2.jpg 王盈錦、林峰輝、胡孝光、黃玲惠、黃義侑、蔡瑞瑩、闕山璋編著,2002,生物醫學材料,合記圖書出版社。 周德程編譯,2000,解剖生理學,昭人出版社。 Alberts B., Johnson A., Lewis J., Raff M., Robert K., Walter P., 1994, Molecular Biology of the Cell(3rd ed), Hardcover. Antman E.M., Colucci W.S., Gatto A.M., Josaphion M.Z., Loscalio J., Pharll S., Popme J.J., 2002, Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease (2 nd), W.B. Saunders Co. Asakawa H., Kobayashi T., 1999, “The effect of coculture with human smooth nuscle cells on the proliferation, the IL-1β secretion, the PDGF production and tube formation of human aortic endothelial cells”, Cell Biochemistry and Function 17: 123-130. Bachetti T., Morbidelli L., 2000, “Endothelial cells in culture: a model for studying vascular function”, Pharmacological Research 42: 9-19. Biological and Biomedical Applications of Stem Cell Research, Board on Life Sciences, National Research Council, Board on Neuroscience and Behavioral Health, Institute of Medicine, 2002, Stem cells and the future of regenerative medicine, National Academy Press. Byrom D., 1991, Biomaterials, Hardcover. Chalupowicz C.J., Chowdhury Z.A., Bach T.L., Barsigian C., Martinez J., 1995, “Fibrin II induces endothelial cell capillary tube formation”, Journal of Cell Biology 130: 207-215.Bachetti T., Morbidelli L., 2000, “Endothelial cells in culture: a model for studying vascular function”, Pharmacological Research 42: 9-19. Cheung D.T., Perelman N., Ko E.C., Nimni M.E., 1985, “Mechanism of crosslinking of proteins by glutaraldehyde. III: Reactions with collagen in tissues”, Connective tissue research 13: 109-115. Chu F.L., Lu A., Liszkowski M., Sipehia R., 1999, “Enhanced growth of animal and human endothelial cells on biodegradable polymers”, Biochimica et Biophysica Acta 1472: 479-485. Djabourov M., Lechaire J.P., Gaill F., 1993, “Structure and rheology of gelatin and collagen gels”, Biorheology 30: 191-205. Dzau V.J., Braun-dullaeus R.C., Sedding D.G., 2002, “Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies”, Nature Medicine 8: 1249-1256. Fischer G.M., Llaurado J.G., 1971, “Connectibe tissue composition of human coronary artery and its relationship to divalent cation context”, Angiology 22: 31-6. Fittkau M.H., Zilla P., Bezuidenhout D., Lutolf M.P., Human P., Hubbell J.A., Davies N., 2005, “The selective modulation of endothelial cell mobility on RGD peptide containing surfaces by YIGSR peptides”, Biomaterials 26: 167-174. Gelman R.A., Poppke D.C., Piez K.A., 1979, “Collagen fibril formation in vitro. The role of the nonhelical terminal regions”, The Journal of biological chemistry 254: 11741-11745. Grassl E.D., Oegema T.R., Tranquillo R.T., 2003, “A fibrin-based arterial media equivalent”, Journal of Biomedical Materials Research 66A: 550-561. Greisler H.P., 1991, “New biologic and synthetic biological prostheses”, Medical Intelligence unit 1:1-91. Gross J., Kirk D., 1958, “The Heat Precipitation of Collagen from Neutral Salt Solutions: Some Rate-Regulating Factors”, The Journal of biological chemistry 233: 355-362. Guyton A.C., Hall J.E., 1997, Human physiology and mechanisms of disease, Saunders. Hsu S.H., Sun S.H., Chen D.C., 2003, “Improved retention of endothelial cells seeded on polyurethane small-diameter vascular grafts modified by a recombinant RGD-containing protein”, Artificial Organs 27: 1068-1078. Hubbel J.A., 1995, “Biomaterials in tissue engineering”, Bio Technology 13: 565-576. Iwai S., Sawa Y., Ichikawa H., Taketani S., Uchimura E., Chen G., Hara M., Miyake J., Matsuda H., 2004, “Biodegradable polymer with collagen microsponge serves as a new bioengineered cardiovascular prosthesis”, Journal of Thoracic and Cardiovascular Surgery 128: 472-479. Junquerira, 1997, 王世晞、陳德皓、徐志宏編譯,基礎組織學,藝軒圖書出版社。 Kakade M.L., Liener I.E., 1969, “Determination of Available Lysine in Proteins”, Analytical Biochemistry 27: 273-280. Khor E., 1997, “Methods for the Treatment of Collagenous Tissue for Bioprostheses”, Biomaterials 18: 95-105. Lanza R.P., Langer R, Vacanti J, 2001, Principles of Tissue Engineering (2nd ed), Hardcover. Lee C.H., Singla A., Lee Y., 2001, “Biomedical applications of collagen”, International Journal of Pharmaceutics 221: 1 – 22. Miller E.J., Rhodes R.K., 1982, “Preparation and characterization of the different types of collagen”, Methods in enzymology 82: 59-62. Mitchell S.L., Niklason L.E., 2003, “Requirements for growing tissue- engineered vascular grafts”, Cardiovascular Pathology 12: 59-64. Moore K.L., Dalley II A.F., Donohoe L.S., Moore M.E., 1999, Clinically oriented anatomy, Lippincott Williams & Wilkins. Mosmann T., 1983, “Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays ”, Journal of Immunological Methods 65: 55-63. Neidert M.R., Oegema T.R., Tranquillo R.T., 2001, “Fibein as an alternative biopolymer to type I collagen for tissue-equivalent fabrication”, Bioengineering Conference;BED-vVol. 50. O’Donnell T.F., Mackey W., McCullough J.L., Maxwell S.L., Farber S.P., Dejerling R.A., Callow R.D., 1984, “Correlation of operative findings with angiographic and non-invasive hemodynamic factors associated with failure of PTFE grafts”, Journal of vascular surgery 1: 136-148. Olde Damink L.H.H., 1995, “Glutaraldehyde as crosslinking agent for collagen-based biomaterials”, Journal of materials science : materials in medicine 6: 460-472. Orban J.M., Wilson L.B., Kofroth J.A., El-Kurid M.S., Maul T.M., Vorp D.A., 2004, “Crosslinking of collagen gels by transglutaminase”, Journal of Biomedical Materials Research 68A: 756-762. Park J.B., Bronzino J.D., 2003, Biomaterials : principles and applications, Hardcover. Reis R.L., Roman J.S., 2005, Biodegradable systems in tissue engineering and regenerative medicine, CRC Press. Roskelley C.D., Srebrow A., Bissell M.J., 1995, “A hierarchy of ECM-mediated signaling regulates tissue-specific gene expression”, Current Opinion in Cell Biology 7: 736-747. Ross J.J., R.T. Tranquillo, 2003, “ECM gene expression correlates with in vitro tissue growth and development in fibrin gel remodeled by neonatal smooth muscle cells”, Matrix Biology 22: 477-490. Rutherford R.B., 1995, Vascular surgery (4th ed). Sluijter J.P., Smeets M.B., Velema E., Pasterkamp G., de Kleijn D.P., 2004, “Increase in collagen turnover but not in collagen fiber content is associated with flow-induced arterial remodeling”, Jjournal of Vascular Research 41: 546-555. Thomas O.D., Dale A, 2000, “Endothelial signal integration in vascular assembly”, Annual Review of Physiology 62: 649-671. Wang H., Keiser J.A., 1998, “Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1”, Ciuculation Research, 83: 832-840. Weinberg C.B., Bell E., 1986, “A blood vessel model constructed from collagen and cultured vascular cells”, Science, 231: 397-400. Wood G.C., Keech M.K., 1960, “The function of fibrils form collagen solutions”, The Biochemical journal 75: 588-589. Yamada Y., Kleinman H.K., 1992, “Functional domains of cell adhesion molecules”, Current Opinion in Cell Biology 4: 819-823. Zammaretti P., Zisch A.H., 2005, “Adoult ‘endothwlial progenitor cells’ renewing vasculature”, The Intemational Journal of Biochemistry & Cell Biology 37: 493-503. Zeeman R., Dijkstra P.J. Wachem P.B., Luyn M. J.A., Hendriks M., Cahalan P.T., Feijen J., 1999, “Crosslinking and modification of dermal sheep collagen using 1,4-butanediol diglycidyl ether”, Journal of Biomedical Materials Research 46: 424-433. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38835 | - |
dc.description.abstract | 每年冠狀動脈繞道術(血管直徑<4 mm)普遍被選用來治療心血管疾病病患,而臨床上大多以自體移植的隱靜脈、合成材料的血管移植替代物或去除細胞的組織(異體、異種移植的臍帶或血管)來做為血管移植替代物。然而,因上述的血管移植替代物有著來源、口徑的限制且容易再次引起血栓及血管再狹窄和嚴重的發炎免疫反應等缺點。為了改善上述這些缺點,本研究乃以組織工程的方式,將豬皮萃取之第一型膠原蛋白當作基材,形成具備適當機械性質特性及良好生物相容性的支架。另外,再接種內皮細胞、平滑肌細胞並以共同培養方式,進而促使血管細胞貼附、增生以及分化,出現類似血管之結構。動物實驗中,血管移植替代物(長約5 mm,內徑約3 mm)皆能成功穩合端部銜接端部(end-to-end anastomoses)接枝於下腔靜脈,不論支架是否有接種細胞,內皮細胞皆能完整鋪列生長於支架上,且皆沒有血栓的形成,但有接種細胞之血管移植替代物,除了形成接觸血液面之內皮細胞層外,並經免疫染色鑑定,於次表面已具有完整環狀之平滑肌細胞的表現,而無接種細胞之血管移植替代物則無平滑肌細胞的出現。相信未來能應用於冠狀動脈繞道移植之小口徑之血管替代物。 | zh_TW |
dc.description.abstract | In recent decades, cardiovascular disease is becoming the leading cause of death in developed countries only inferior to cancer. Coronary artery bypass graft surgery (for small diameter < 4 mm graft) is performed annually in the world, making it one of the most commonly performed major operations. Autogenous saphenous veins, synthetic grafts, or acellular human umbilical veins are presently used as replacement arteries in surgical procedures. However, limited availability of the graft and the limited conduit diameter troubled clinical doctors. In addition, the recurrences of obstructed blood vessels, thrombosis, and eliciting serious immune response challenged researchers as well. In order to overcome these inconvenience, tissue engineering offers the hope of delivering the replacement function in a much more cost-effective and beneficial way. The objective of this study is to fabricate an adequate blood vessel replacement with suitable mechanical property and biocompatibility for clinical applications. In this study, we are going to prepare blood vessel based on type I collagen by tissue engineering technique. Endothelial cells and smooth muscle cells harvested from endocardium, bladder, and blood vessel will be seeded on a preformed scaffold for cell proliferation and differentiation, and finally developed into a physiologically functional blood vessel. In the animal study, we found that endothelial cells could survive and smoothly cover the whole surface area of the scaffold both in non cell-seeding group and cell-seeding group. However, smooth muscle cells only showed positive reaction by immunostain in the cell-seeding group, but negative reaction in non cell-seeding group. We expect that the tissue-engineering vessel would have the properties of good biocompatibility, anti-thrombosis, resistance to infection, low immunogenicity, and might prevent from platelet aggregation and minimal tissue infiltration. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T16:48:25Z (GMT). No. of bitstreams: 1 ntu-94-R92548001-1.pdf: 3517045 bytes, checksum: 842070ff4a4822b6adfaa59bf63c0b59 (MD5) Previous issue date: 2005 | en |
dc.description.tableofcontents | 目錄‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥I
圖目錄‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥V 表目錄‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥VIII 中文摘要‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥IX 英文摘要‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥X 第一章 序論 1.1 前言‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥1 1.2 血管‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥1 1.2.1 血管的構造‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥1 1.3 冠狀動脈疾病‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥3 1.4 血管再狹窄病變‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥4 1.5 臨床治療方式‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥6 1.5.1 飲食治療‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥6 1.5.2 藥物治療‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥6 1.5.3 冠狀動脈介入性治療(即俗稱的心導管手術)‥‥‥‥‥‥‥‥8 1.5.4 冠狀動脈支架植入術‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥10 1.5.5 冠狀動脈繞道術‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥11 1.6 血管移植物的種類‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥12 1.7 研究目的‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥13 第二章 理論基礎 2.1 組織工程‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥15 2.1.1 細胞‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥16 2.1.1.1 成熟細胞‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥16 2.1.1.2 幹細胞‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥17 2.1.2 支架‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥18 2.1.3 訊息‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥18 2.2 細胞外基質‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥19 2.2.1 細胞外基質蛋白與受器‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥20 2.2.2 膠原蛋白‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥23 2.2.2.1 膠原蛋白的結構‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥24 2.2.2.2 膠原蛋白之萃取純化‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥26 2.2.2.3 膠原蛋白之生物學特性及加工製備於生醫上之應用‥‥‥‥‥28 第三章 實驗方法 3.1 實驗儀器‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥33 3.2 實驗藥品‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥34 3.3 實驗方法與流程‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥36 3.3.1第一型膠原蛋白膜(Type I collagen membrane )支架製備‥‥‥37 3.3.2 細胞培養‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥39 3.3.2.1 內皮細胞(Endothelial cell, EC)‥‥‥‥‥‥‥‥‥‥‥‥‥‥39 3.3.2.2 平滑肌細胞(Smooth muscle cell, SMC)‥‥‥‥‥‥‥‥‥‥40 3.4 支架材料分析‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥42 3.4.1 傅立葉轉換紅外線光譜儀分析‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥42 3.4.2 支架交聯程度(自由胺基含量)分析‥‥‥‥‥‥‥‥‥‥‥‥42 3.4.3 掃瞄式電子顯微鏡分析‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥43 3.4.4 機械強度分析‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥43 3.5 細胞分析‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥44 3.5.1 免疫化學酵素分析‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥44 3.5.2 即時反轉錄聚合酶鍊鎖反應real-time reverse transcription polymerase chain reaction (real-time RT-PCR) ‥‥‥‥‥‥‥‥‥‥‥‥‥‥46 3.6 細胞接種‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥47 3.7 動物實驗‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥49 3.7.1 皮下植入‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥49 3.7.2 下腔靜脈血管接枝‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥50 3.8 組織化學分析‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥51 3.8.1 組織切片製作‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥51 3.8.1.1 自動儀器處理組織原則及步驟‥‥‥‥‥‥‥‥‥‥‥‥‥‥51 3.8.1.2 石蠟塊之包埋匣(cassette)包埋‥‥‥‥‥‥‥‥‥‥‥‥‥52 3.8.1.3 組織切片機‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥52 3.8.2 組織切片脫蠟‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥53 3.8.3 蘇木紫-伊紅(Hematoxylin-eosin, H&E)染色‥‥‥‥‥‥‥‥53 3.8.4 Alcian blue, pH 2.5 染色‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥53 3.8.5 Masson氏三色(trichrome)法染結締組織‥‥‥‥‥‥‥‥‥‥54 3.8.6免疫化學酵素分析‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥55 第四章 結果與討論 4.1 支架材料之分析‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥58 4.1.1 支架材料之傅立葉轉換紅外線光譜儀分析‥‥‥‥‥‥‥‥‥‥59 4.1.2 支架材料之交聯程度(自由胺基含量)分析‥‥‥‥‥‥‥‥‥60 4.1.3 支架材料之掃瞄式電子顯微鏡分析‥‥‥‥‥‥‥‥‥‥‥‥‥61 4.1.4 支架材料之機械強度分析‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥62 4.2細胞分析(內皮細胞&平滑肌細胞)‥‥‥‥‥‥‥‥‥‥‥‥‥64 4.2.1 免疫螢光酵素分析‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥65 4.2.2即時反轉錄聚合酶鍊鎖反應real-time reverse transcription polymerase chain reaction (real-time RT-PCR) ‥‥‥‥‥‥‥‥‥‥‥‥‥‥66 4.3 體外(in vitro)培養血管移植替代物‥‥‥‥‥‥‥‥‥‥‥‥‥68 4.3.1 掃瞄式電子顯微鏡分析‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥69 4.3.2 蘇木紫-伊紅(Hematoxylin-eosin, H&E)染色‥‥‥‥‥‥‥‥70 4.3.3 Alcian blue, pH 2.5 染色‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥71 4.4 體內(in vivo)皮下培養血管移植替代物‥‥‥‥‥‥‥‥‥‥‥‥72 4.4.1 蘇木紫-伊紅(Hematoxylin-eosin, H&E)染色‥‥‥‥‥‥‥‥73 4.4.2 Masson氏三色(trichrome)法染結締組織‥‥‥‥‥‥‥‥‥‥74 4.4.3 支架降解程度分析‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥75 4.4.4 免疫組織化學分析‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥76 4.5體內(in vivo)下腔靜脈接枝血管移植替代物‥‥‥‥‥‥‥‥‥‥77 4.5.1 蘇木紫-伊紅(Hematoxylin-eosin, H&E)染色‥‥‥‥‥‥‥‥78 4.5.2 Masson氏三色(trichrome)法染結締組織‥‥‥‥‥‥‥‥‥‥80 4.5.1.3 免疫組織化學分析‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥82 第五章 結論‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥86 第六章 未來展望‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥87 第七章 參考文獻‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥88 圖目錄 圖1-1 The structure of blood vessel.‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥2 圖1-2 Coronary artery.‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥4 圖1-3 Arteriosclerosis.‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥6 圖1-4 During the procedure of percutaneous transluminal coronary angioplasty /stent placement.‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥7 圖1-5 Percutaneous Transluminal Coronary Angioplasty (PTCA).‥‥‥‥8 圖1-6 coronary stenting.‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥11 圖1-7 Coronary Artery Bypass Surgery.‥‥‥‥‥‥‥‥‥‥‥‥‥‥12 圖2-1 The tissue engineering triad.‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥16 圖2-2 Triple-stranded helix of collagen.‥‥‥‥‥‥‥‥‥‥‥‥‥‥26 圖2-3 The conformation of collagen.‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥26 圖2-4 Simplified representation of monomeric glutaraldehyde reaction with amino groups on collagen to form cross-links. ‥‥‥‥‥‥‥‥‥31 圖2-5 Glutaraldehyde and the forms it takes in aqueous media.‥‥‥‥‥31 圖3-1 實驗流程圖。‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥36 圖3-2 第一型膠原蛋白(Type I collagen)萃取及交聯製作流程。‥‥‥38 圖3-3 內皮細胞、平滑肌細胞培養流程。‥‥‥‥‥‥‥‥‥‥‥‥‥41 圖3-4 Reaction of TNBS with free amino group.‥‥‥‥‥‥‥‥‥‥‥43 圖3-5免疫螢光酵素分析細胞之實驗流程。‥‥‥‥‥‥‥‥‥‥‥‥45 圖3-6 細胞接種流程圖。‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥49 圖3-7免疫化學酵素分析組織切片之實驗流程。‥‥‥‥‥‥‥‥‥‥57 圖4-1 膠原蛋白纖維之電子顯微鏡(SEM)觀察。‥‥‥‥‥‥‥‥‥58 圖4-2 Simplified representation of monomeric glutaraldehyde reaction with amino groups on collagen to form cross-links.‥‥‥‥‥‥‥‥‥59 圖4-3傅立葉紅外線光譜分析type I膠原蛋白未經交聯和經戊二醛化學交聯反應後之特定官能基的波長位置及鍵結變化。‥‥‥‥‥‥‥60 圖4-4 經交聯反應之第一型膠原蛋白膜(type I collagen membrane)之電子顯微鏡(SEM)孔洞大小的觀察。(A)表面;(B)截面。‥62 圖4-5 經交聯反應之type I膠原蛋白,以縫線縫製成管狀。‥‥‥‥‥64 圖4-6 雷射掃瞄光譜共軛焦顯微鏡(Confocal Scanning Microscope)觀察。(A)內皮細胞(endothelial cell)之Factor VIII(von Willebrand Factor)免疫螢光(TRITC)蛋白染色(紅色);(B)平滑肌細胞(smooth muscle cell)之α-actin免疫螢光(FITC)蛋白染色(綠色)。‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥65 圖4-7 real-time RT-PCR之內皮細胞eNOS, VEGFR-KDR, beta-actin基因表現。‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥67 圖4-8洋菜膠電泳之內皮細胞eNOS, VEGFR-KDR, beta-actin的基因表現。 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥68 圖4-9接種細胞之支架的電子顯微鏡(SEM)觀察SEM(A)內皮細胞接種於支架之表面(B)平滑肌細胞接種於支架之表面(C)平滑肌細胞接種於支架之截面。‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥70 圖4-10 以不同培養時程A, B, C組之H&E染色(100X)。‥‥‥‥‥71 圖4-11以培養時程C組之alcian blue染色(100X)。‥‥‥‥‥‥‥‥72 圖4-12 於體外培養10天後,將管狀支架植入於老鼠後背部皮下3週之 H&E染色(刻度尺為200μm)。(A)和(B)為控制組,不含細胞之管狀支架;(C)和(D)為實驗組,含細胞之管狀支架。‥74 圖4-13 於體外培養10天後,將管狀支架植入於老鼠後背部皮下3週之Masson’s trichrome染色(刻度尺為200μm)。(A)和(B)為控制組,不含細胞之管狀支架;(C)和(D)為實驗組,含細胞之管狀支架(圖中所示之綠色為膠原蛋白;紅色為肌肉細胞;黑色為細胞核;鮮紅色為紅血球。)。‥‥‥‥‥‥‥‥‥‥‥‥75 圖4-14 於體外培養10天後,將管狀支架植入於老鼠後背部皮下3週之降解程度分析(n=14)。‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥76 圖4-15 於體外培養10天後,將管狀支架植入於老鼠後背部皮下3週之免疫染色---DAB褐色呈色(刻度尺為20μm)。(A)(B)為為控制組,不含細胞之管狀支架;(C)(D)為實驗組,含細胞之管狀支架。 (A)(C)染vWf,(B)(D)染α-actin。圖中所示之黑色三角方塊表示EC所分泌的vWf,白色三角方塊表示SMC所分泌的α-actin。‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥77 圖4-16 於體外培養10天後,將管狀支架植入於wistar rat老鼠下腔靜脈(圖中所示之黑色箭號表示血管移植替代物(長度約為5 mm,內徑約為1∼2 mm),白色三角方塊表示下腔靜脈。)。‥‥‥‥‥‥78 圖4-17 於體外培養10天後,將管狀支架植入於老鼠下腔靜脈6和12週之H&E染色(刻度尺黑色為200μm,白色為20μm)(白色箭頭為血栓)。(A)(B)為正常組織;6週(C)(D)12週(G)(H)為控制組,不含細胞之管狀支架;6週(E)(F)12週(I)(J)為實驗組,含細胞之管狀支架。*為血管移植替代物。‥‥‥‥79 圖4-18 於體外培養10天後,將管狀支架植入於老鼠下腔靜脈6和12週之Masson’s trichrome染色(刻度尺黑色為200μm;,白色為20μm)(白色箭頭為血栓)。(A)(B)為正常組織;6週(C)(D)12週(G)(H)為控制組,不含細胞之管狀支架;6週(E)(F)12週(I)(J)為實驗組,含細胞之管狀支架。*為血管移植替代物。‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥81 圖4-19 於體外培養10天後,將管狀支架植入於老鼠下腔靜脈6和12週之免疫染色---DAB褐色呈色染色(刻度尺黑色為5μm,白色為20μm)。(A)(B)為正常組織;6週(C)(D)12週(G)(H)為控制組,不含細胞之管狀支架;6週(E)(F)12週(I)(J)為實驗組,含細胞之管狀支架。(A)(C)(E)(G)(I)染vWf;(B)(D)(F)(H)(J)染α-actin。‥‥‥‥‥‥‥‥‥‥‥‥‥84 表目錄 表1-1 The functions of endothelial cell.‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥3 表2-1 The variety of human stem cell.‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥17 表2-2 The major cell adhesion molecules.‥‥‥‥‥‥‥‥‥‥‥‥‥19 表2-3 Selected membraners of the integrin receptor class and their ligands. ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥22 表2-4 Selected cell binding domain sequences of extracellular matrix protein. ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥23 表2-5 膠原蛋白的型式及組成。‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥24 表2-6 The relationship of collagen precipitation and environment.‥‥‥‥28 表2-7 Advatages and disadvantages of collagen as a biomaterial.‥‥‥‥29 表2-8 各種型態之膠原蛋白及其在醫學上之應用。‥‥‥‥‥‥‥‥‥32 表3-1 The process of cell seeding and tubular formation.‥‥‥‥‥‥‥‥48 表4-1 經交聯反應之type I膠原蛋白膜之機械性質分析。‥‥‥‥‥‥64 表4-2 細胞培養時程(天)。‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥68 | |
dc.language.iso | zh-TW | |
dc.title | 組織工程之血管移植替代物 | zh_TW |
dc.title | Tissue Engineering of Vascular Graft | en |
dc.type | Thesis | |
dc.date.schoolyear | 93-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 孫瑞昇(Jui-Sheng Sun) | |
dc.contributor.oralexamcommittee | 王盈錦,陳克紹(Ko-Shao Chen) | |
dc.subject.keyword | 組織工程,血管移植替代物,第一型膠原蛋白,血管內皮細胞,血管平滑肌細胞, | zh_TW |
dc.subject.keyword | tissue engineering,vascular graft,collagen type I,endothelial cell,smooth muscle cell, | en |
dc.relation.page | 90 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2005-06-27 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
顯示於系所單位: | 醫學工程學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-94-1.pdf 目前未授權公開取用 | 3.43 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。